Experts in B-cell lymphoma research discuss an updated analysis from a phase I study of mivavotinib for relapsed/refractory B-cell lymphoma, focusing on diffuse large B-cell lymphoma. They delve into the drug's mechanism of action, patient enrollment, treatment protocol, response rates, efficacy on DLBCL responders, median response duration, ORR in subgroups, progression-free survival rates, treatment emergent adverse events, and SYK as a potential therapeutic target for B-cell lymphomas.
